1文献来源Cortes J,Cescon DW,Rugo HS,et al.Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple⁃negative breast cancer(KEYNOTE⁃355)...1文献来源Cortes J,Cescon DW,Rugo HS,et al.Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple⁃negative breast cancer(KEYNOTE⁃355):A randomised,placebo⁃controlled,double⁃blind,phase 3 clinical trial[J].Lancet,2020,396(10265):1817-1828.展开更多
文摘1文献来源Cortes J,Cescon DW,Rugo HS,et al.Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple⁃negative breast cancer(KEYNOTE⁃355):A randomised,placebo⁃controlled,double⁃blind,phase 3 clinical trial[J].Lancet,2020,396(10265):1817-1828.